The Company
The Company
Promore Pharma in Brief
Vision and Strategy
Market
Team
Board of Directors
Projects
Projects
Ropocamptide – Healing of Chronic Wounds
Publications
Investors
Investors
Promore Pharma on Nasdaq First North Growth Market
Certified Adviser
The Share
Shareholders
Warrant Programs
Share capital development
Analysts
Financial Reports
Press Releases
Prospectuses
Presentations and Events
Calendar
Subscribe
Corporate Governance
Corporate Governance
Corporate Governance
General Meeting
General Meetings
Nomination Committee
Nomination Committees
The Board of Directors
Board of Directors
The Management
Management
Remunerations and Remuneration Committee
Auditor and Audit Committee
Articles of Association
Certificate of Registration
Media
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Contact
Office
Investors
Media
Svenska
The Company
Promore Pharma in Brief
Vision and Strategy
Market
Team
Board of Directors
Projects
Ropocamptide – Healing of Chronic Wounds
Publications
Investors
Promore Pharma on Nasdaq First North Growth Market
Certified Adviser
The Share
Shareholders
Warrant Programs
Share capital development
Analysts
Financial Reports
Press Releases
Prospectuses
Presentations and Events
Calendar
Subscribe
Corporate Governance
Corporate Governance
General Meeting
General Meetings
Nomination Committee
Nomination Committees
The Board of Directors
Board of Directors
The Management
Management
Remunerations and Remuneration Committee
Auditor and Audit Committee
Articles of Association
Certificate of Registration
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Office
Investors
Media
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Erik Magnusson
Chief Financial Officer (CFO)
+46 70 856 52 45
Press Releases
Regulatory press releases
Non-regulatory press releases
All press releases
All years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2013
September 18, 2023
NOTICE OF EXTRAORDINARY GENERAL MEETING PROMORE PHARMA AB (PUBL)
August 30, 2023
Interim report January – June 2023
August 16, 2023
Promore Pharma engages Erik Penser Bank as liquidity provider
June 27, 2023
Report from the Annual General Meeting of Promore Pharma AB held on 27 June 2023
June 22, 2023
Promore Pharma reduces costs and explores the conditions for a reverse acquisition
May 25, 2023
Promore Pharma’s AGM related Documents Published
May 23, 2023
Interim report January – March 2023
May 9, 2023
Promore Pharma’s Annual Report 2022
April 20, 2023
Promore Pharma AB changes the AGM date to June 27
April 20, 2023
Promore Pharma reports outcome from clinical Phase II study with ensereptide
February 28, 2023
Year-end report, 2022
November 29, 2022
Interim report January – September 2022
November 23, 2022
Nomination Committee Appointed for the Annual General Meeting 2023 in Promore Pharma
November 1, 2022
Promore Pharma provides an update on the Phase II clinical trial with ensereptide
August 30, 2022
Promore Pharma Interim report January – June 2022
June 13, 2022
The last clinic visit conducted in Promore Pharma’s phase II study of ensereptide
May 17, 2022
Report from the Annual General Meeting of Promore Pharma AB held on 17 May 2022
May 17, 2022
Promore Pharma — interim report January-March 2022
April 26, 2022
Promore Pharma’s Annual Report 2021 and AGM related Documents Published
April 12, 2022
NOTICE OF ANNUAL GENERAL MEETING PROMORE PHARMA AB (PUBL)
March 17, 2022
Promore Pharma has reached recruitment goal in clinical trial of ensereptide
February 16, 2022
Interim report January – December 2021
February 16, 2022
First patient recruited to Promore Pharma’s clinical trial regarding scarring according to plan
January 31, 2022
Promore Pharma deregisters warrants
November 23, 2021
Interim report January – September 2021
November 16, 2021
Nomination Committee Appointed for the Annual General Meeting 2022 in Promore Pharma
November 9, 2021
Promore Pharma receives permits to start a phase II clinical trial regarding scar prevention
October 25, 2021
Promore Pharma announces that scientific article has been published on clinical study results with ropocamptide for venous leg ulcers
September 13, 2021
Promore Pharma receives delivery of hyaluronic acid from Italian manufacturer Fidia
August 24, 2021
Interim report January – June 2021
July 20, 2021
The rights issue is registered and the trading in Paid Subscription Shares ceases
June 22, 2021
Outcome in Promore Pharma’s rights issue
June 2, 2021
Promore Pharma publishes prospectus
May 27, 2021
Promore Pharma informs about the last day of trading to receive subscription rights
May 27, 2021
Interim report January – March 2021
May 27, 2021
Report from an extra General Meeting of Promore Pharma AB held on 27 May 2021
May 27, 2021
Report from the Annual General Meeting of Promore Pharma AB held on 27 May 2021
May 10, 2021
Notice of Extraordinary General Meeting in Promore Pharma AB (publ)
May 7, 2021
Promore Pharma AB intends to carry out a fully secured rights issue in order to implement the new strategy
May 6, 2021
Promore Pharma’s Annual Report 2020 and AGM related Documents Published
April 28, 2021
Promore Pharma signs agreement on production of hyaluronic acid with Italian manufacturer Fidia
April 27, 2021
NOTICE OF ANNUAL GENERAL MEETING PROMORE PHARMA AB (PUBL)
March 31, 2021
Promore Pharma deregisters warrants
March 31, 2021
Promore Pharma updates its strategy and focuses on scar prevention
February 23, 2021
Year-end report 2020
January 20, 2021
Promore Pharma changes Certified Adviser to Erik Penser Bank AB
November 24, 2020
Interim report January – September 2020
November 20, 2020
Clarification of outcome in the clinical trial HEAL LL-37
November 19, 2020
Promore Pharma announces positive results from Phase IIb study of ropocamptide in the treatment of venous leg ulcers
August 25, 2020
Promore Pharma AB (publ) Interim report January – June 2020
May 28, 2020
Promore Pharma Appoints Erik Magnusson as Chief Financial Officer
May 26, 2020
Report from the Annual General Meeting of Promore Pharma AB held on 26 May 2020
May 26, 2020
Promore Pharma AB (publ) Interim report January – March 2020
May 5, 2020
Promore Pharma’s Annual Report 2019 Published
April 22, 2020
Notice of Annual General Meeting in Promore Pharma AB (publ)
April 2, 2020
Promore Pharma´s CFO leaves the company in 2020
March 24, 2020
Promore Pharma reached the targeted number of patients completing treatment in the HEAL LL-37 Phase IIb clinical trial
February 18, 2020
Promore Pharma AB (publ) Year-end report 2019
December 10, 2019
Promore Pharma has finalized recruitment of patients in HEAL LL-37 early
December 2, 2019
Promore Pharma’s rights issue completed
November 22, 2019
Promore Pharma publishes supplementary prospectus in connection with the ongoing rights issue
November 22, 2019
Promore Pharma AB (publ) Interim report January – September 2019
November 12, 2019
Promore Pharma publishes prospectus in connection with rights issue
October 22, 2019
Report from the Extraordinary Shareholders’ Meeting of Promore Pharma AB held on 22 October 2019
October 21, 2019
Promore Pharma engages ABG Sundal Collier as liquidity provider
October 7, 2019
Notice of Extraordinary Shareholders’ Meeting in Promore Pharma AB (publ)
October 4, 2019
Promore Pharma Promore Pharma carries out a rights issue of approximately SEK 75 million, underwritten up to 80 percent, and intends to publish its interim report early
August 28, 2019
Promore Pharma AB (publ) Interim report January – June 2019
June 20, 2019
Promore Pharma has recruited half of the patients in HEAL LL-37
May 21, 2019
Report from the Annual General Meeting of Promore Pharma AB held on 21 May 2019
May 21, 2019
Promore Pharma AB (publ) Interim report January – March 2019
April 16, 2019
Notice of Annual General Meeting in Promore Pharma AB (publ)
February 26, 2019
Promore Pharma AB (publ) Year-end report 2018
February 1, 2019
Promore Pharma modifies its Phase III trial of PXL01 and expands the number of clinics in the study
November 23, 2018
Promore Pharma AB (publ) Interim report January – September 2018
November 19, 2018
Promore Pharma receives approval for Phase III study with PXL01 in India
October 23, 2018
Promore Pharma has had a successful meeting with the FDA regarding PXL01
October 1, 2018
Promore Pharma has enrolled first patient in HEAL LL-37 in Poland
August 22, 2018
Promore Pharma receives approval for Phase IIb trial with LL-37 in Poland
August 20, 2018
Interim report January – June 2018
July 3, 2018
Promore Pharma receives approval for Phase IIb trial with LL-37
May 16, 2018
Report from the Annual General Meeting of Promore Pharma AB held on 16 May 2018
May 16, 2018
Promore Pharma AB (publ) Interim report January – March 2018
May 7, 2018
Promore Pharma Out-licenses PXL01 for Spinal Surgery to PharmaResearch Products Ltd
April 25, 2018
Promore Pharma 2017 Annual report published
April 11, 2018
Notice of Annual General Meeting in Promore Pharma AB (publ)
February 15, 2018
Promore Pharma Regains Rights for PXL01 Manufacturing
February 6, 2018
Year-end report 2017
January 2, 2018
Promore Pharma Adjusts Plans for PXL01 in North America
November 21, 2017
Interim report January – September 2017
November 14, 2017
Promore Pharma Signs Out-licensing Agreement with Transdermal Therapeutic Technologies for its Peptide DPK-060
August 30, 2017
Interim report January – June 2017
